Open AccessEndoscopic eradication therapy for Barrett's oesophagus: state of the art
Author(s) -
Jennifer M. Kolb,
Sachin Wani
Publication year - 2020
Publication title -
current opinion in gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.165
H-Index - 83
eISSN - 1531-7056
pISSN - 0267-1379
DOI - 10.1097/mog.0000000000000650
Subject(s) - medicine , barrett's oesophagus , dysplasia , barrett's esophagus , intestinal metaplasia , esophagectomy , carcinoma in situ , gastroenterology , adenocarcinoma , esophagus , metaplasia , carcinoma , esophageal cancer , cancer
Barrett's oesophagus is the only identifiable precursor lesion to oesophageal adenocarcinoma. The stepwise progression of Barrett's oesophagus to dysplasia and invasive carcinoma provides the opportunity to intervene and reduce the morbidity and mortality associated with this lethal cancer. Several studies have demonstrated the efficacy and safety of endoscopic eradication therapy (EET) for the management of Barrett's oesophagus related neoplasia. The primary goal of EET is to achieve complete eradication of intestinal metaplasia (CE-IM) followed by enrolment of patients in surveillance protocols to detect recurrence of Barrett's oesophagus and Barrett's oesophagus related neoplasia.